How did a gut hormone that disappeared in seconds become one of the biggest drug classes in the world?

In this episode, I walk through the story of GLP-1, from early scientific discovery and the Gila monster breakthrough to Novo Nordisk’s drug design strategy, Eli Lilly’s competitive push, and the shift that turned GLP-1 from a diabetes treatment into something much bigger.

This is a story about how a hard biological problem became a pharmaceutical platform, and how that platform began to change the way medicine thinks about obesity, metabolism, and chronic disease.

Timestamps

• 00:08 Intro: The 90-Second Hormone
• 02:23 The Gut’s Hidden Signal
• 05:01 The Discovery of GLP-1
• 10:32 The Gila Monster Breakthrough
• 16:04 Novo Solves the Delivery Problem
• 19:43 How GLP-1 Became a Platform
• 25:46 Beyond Diabetes
• 30:28 Lilly Raises the Benchmark
• 32:43 The Broader Implications of GLP-1
• 43:22 The future of GLP-1
• 49:14 When the Science Meets the System